Suchen
Spero Therapeutics Inc
SPROZur Watchlist hinzufügen
2.200USD
-0.020-0.90%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
127.38MMarktkapitalisierung
7.92KGV TTM
mehr Informationen über Spero Therapeutics Inc Unternehmen
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Inc Informationen
BörsenkürzelSPRO
Name des UnternehmensSpero Therapeutics Inc
IPO-datumNov 02, 2017
CEORajavelu (Esther)
Anzahl der mitarbeiter32
WertpapierartOrdinary Share
GeschäftsjahresendeNov 02
Addresse675 Massachusetts Ave Ste 14
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02139-3309
Telefon18572421600
Websitehttps://sperotherapeutics.com/
BörsenkürzelSPRO
IPO-datumNov 02, 2017
CEORajavelu (Esther)
Führungskräfte von Spero Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
-36.36%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Spero Therapeutics Inc?
Die fünf größten Anteilseigner von Spero Therapeutics Inc sind: Dr. Ankit Mahadevia, M.D.
Wie viele Institutionen halten Anteile an Spero Therapeutics Inc (SPRO)?
Mit Stand vom 2026Q1 halten 117 Institutionen Anteile an Spero Therapeutics Inc, mit einem Gesamtmarktwert von etwa 11.81M, was 20.40% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1291189.00 gestiegen.
Was ist die größte Einnahmequelle von Spero Therapeutics Inc?
Am 2026Q1 erzielte das Geschäft mit Collaboration Revenue Related Party für Spero Therapeutics Inc den höchsten Umsatz in Höhe von 47.03M, was 70.41% des Gesamtumsatzes entspricht.